Lantheus控股 LNTH 深 沪
已收盘 08-15 16:00:00 美东时间
54.18
-0.290
-0.53%
华盛通- 最 高54.85
- 今 开54.52
- 成交量 122.17万股
- 最 低 53.39
- 昨 收 54.47
- 总市值 37.48亿
- 52周最高 118.21
- 市盈率 静 12.42
- 换手率 1.77%
- 52周最低 47.25
- 委 比 98.33%
- 总股本 6918.58万
- 历史最高 126.8899
- 量 比 0.53
- 振 幅 2.68%
- 历史最低 1.76
- 每 手 1
- 风险率 13.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lantheus drops as Truist downgrades after Q2 miss
Shares of Lantheus Holdings (NASDAQ:LNTH) fell ~4% on Tuesday after Truist downgraded the radiopharmaceutical company to Hold from Buy, citing concerns over its Q2 2025 financials, which missed Street...
08-13 03:21
4 Analysts Assess Lantheus Holdings: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 4 analysts h...
08-12 22:01
Lantheus CCO Amanda Morgan Takes Leave of Absence
Lantheus ( ($LNTH) ) just unveiled an announcement. Lantheus Holdings, Inc. ann...
08-12 05:31
Mizuho Maintains Outperform on Lantheus Holdings, Lowers Price Target to $70
Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and lowers the price target from $120 to $70.
08-07 21:20
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers BiomX (AMEX:PHGE) shares increased by 42.7% to $0.62 during Wednesday'...
08-06 20:08
Lantheus Holdings Lowers FY2025 Adj EPS Guidance from $6.60-$6.70 to $5.50-$5.70 vs $6.64 Est; Lowers FY2025 Sales Guidance from $1.550B-$1.585B to $1.475B-$1.510B vs $1.573B Est
Lantheus Holdings (NASDAQ:LNTH) lowers FY2025 Adj EPS guidance from $6.60-$6.70 to $5.50-$5.70 vs $6.64 analyst estimate. Lowers FY2025 sales outlook from $1.550 billion-$1.585 billion to $1.475 billion-$1.510 billion vs
08-06 19:03
Lantheus Holdings Q2 Adj. EPS $1.57 Misses $1.67 Estimate, Sales $378.045M Miss $389.097M Estimate
Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.57 per share which missed the analyst consensus estimate of $1.67 by 6.1 percent. This is a 12.78 percent decrease over earnings of $1.80 per share from
08-06 19:02
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
Lantheus Holdings announced the FDA acceptance of a New Drug Application (NDA) for a new F-18 PSMA imaging agent formulation, which could increase batch size by ~50% and enhance supply resilience, improving patient access. The PDUFA date is set for March 6, 2026. If approved, the new formulation may offer efficacy consistent with PYLARIFY, Lantheus’ market-leading PSMA PET agent, and expand accessibility, especially in underserved areas. Prostate...
08-06 10:45
Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. will host a conference call and webcast on August 6, 2025, at 8:00 a.m. ET to discuss its 2025 second-quarter financial results and provide a business update. Participants can register at https://investor.lantheus.com/news-events/calendar-of-events. A replay will be available approximately two hours after the event and archived for 30 days. Lantheus is a leading radiopharmaceutical company dedicated to improving patient ou...
07-23 12:00
